AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

While value has outperformed growth in Europe over the past five years, Europe now represents less than half of equity market ...

On a per-share basis, the Cambridge, Britain-based company said it had net income of 79 cents. Earnings, adjusted for non-recurring costs, came to $1.09 per share. The results met Wall Street ...

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca Plc may sell some of its medicines directly to patients in the US, joining several other drugmakers that have plans to bypass middlemen or are considering them.

(Alliance News) - AstraZeneca raised its dividend as drug growth pushed earnings higher, Barclays launched a new buyback programme after profit jumped while Greggs saw profit fall despite higher sales ...